Trial Profile
Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms KEYNOTE-020
- 03 May 2021 Status changed from active, no longer recruiting to completed.
- 25 Oct 2018 Results (data cutoff date: 31 Dec 2017), published in the Journal of Clinical Oncology.
- 07 Oct 2018 Status changed from recruiting to active, no longer recruiting.